home / stock / ifrx / ifrx articles
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeuti...
Gainers Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday. Eiger BioPharmace...
MAA for vilobelimab was submitted in July MAA has been validated by EMA and is now under review Regulatory submission based on pivotal data from ...
News, Short Squeeze, Breakout and More Instantly...
InflaRx N.V. Company Name:
IFRX Stock Symbol:
NASDAQ Market:
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...